New Data Featured as a Late-Breaking Abstract Support the Potential Clinical Utility of Liquid Biopsies to Aid in the Diagnosis of Breast Cancer in Women with Dense Breast Tissue
Multiple Datasets Further Validate Clinical Utility of Multiplatform Profiling with Caris Molecular Intelligence® in Advancing Molecular Understanding of a Wide Variety of Breast Cancers
IRVING, Tex., Nov. 17, 2015 – Caris Life Sciences®, a leading biotechnology company focused on fulfilling the promise of precision medicine, announces the presentation of data supporting a liquid biopsy approach to improve the accuracy of breast cancer diagnosis for women with dense breast tissue, and six datasets that demonstrate the clinical utility of multiplatform profiling for patients with triple-negative breast cancer and various rare subtypes of breast cancer. The data, to be presented in poster sessions at the 2015 San Antonio Breast Cancer Symposium (SABCS) from December 8-12 in San Antonio, Tex., enriches our understanding of the molecular profiles of rare and aggressive breast cancers, while also identifying specific and actionable mutations.
Accepted as a late-breaking abstract, researchers at Caris Life Sciences developed a unique, non-invasive liquid biopsy method of profiling that is designed to improve the accuracy and safety of breast cancer screening for women with dense breast tissue. This method was developed using Caris’ proprietary, innovative and unbiased profiling platform that identifies novel molecular targets to inform and enhance advanced diagnostics for cancer and other complex diseases.
Six of the posters report on the use of Caris Molecular Intelligence®, the company’s panomic comprehensive tumor profiling service, to facilitate biomarker identification and molecular characterization of breast cancers. Caris Molecular Intelligence incorporates a multiplatform profiling approach that includes gene sequencing (Next-Generation [NGS] and Sanger sequencing), protein expression analysis (immunohistochemistry [IHC]), and gene copy number and translocation analyses (chromogenic or fluorescence in situ hybridization [CISH or FISH]). Investigators used these methods to examine breast tumor samples for underlying molecular alterations that may yield insights into potentially overlapping and/or alternative therapeutic options for patients with rare and aggressive subtypes of breast cancer.
“Biomarker research continues to produce important insights for practicing oncologists, especially those treating patients with rare and aggressive cancers for which treatment options are limited and little evidence is available to guide care,” said Sandeep K. Reddy, M.D., Chief Medical Officer at Caris Life Sciences. “The studies presented at SABCS highlight molecular differences between breast cancer subtypes and identify targetable pathways for further investigation in clinical trials. Collectively, the data demonstrate the clinical utility of molecular profiling to personalize treatment for patients with various types of breast cancer.”
Following is a schedule of notable Caris Life Sciences datasets to be presented at SABCS:
Thursday, December 10, 2015, 7:30 – 9:00 a.m. CT, Halls A-B
Poster Session 2: Detection/Diagnosis: Circulating Markers
- Late-Breaking Abstract: “Adaptive dynamic artificial poly-ligand targeting: Aptamer-based profiling of liquid biopsies to improve accuracy of breast cancer diagnosis in women with dense tissue”, presented by Valeriy Domenyuk Ph.D., Caris Life Sciences. Poster #P2-01-08.
Thursday, December 10, 2015, 5:00 – 7:00 p.m. CT, Halls A-B
Poster Session 3: Prognostic and Predictive Factors: Response Predictors – Biomarkers and Other Factors
- “Biomarker comparison between androgen receptor-positive-triple-negative breast cancer (AR + TNBC) and quadruple-negative breast cancer (QNBC),” presented by Joanne Xiu, Ph.D., Caris Life Sciences. Poster #P3-07-26.
- “Distinct biomarker features in triple-negative breast cancer metastases to the brain, liver, and bone,” presented by Joanne Xiu, Ph.D., Caris Life Sciences. Poster #P3-07-27.
- “Molecular profiling comparison of BRCA1/2-mutated and BRCA1/2 non-mutated triple-negative breast cancer (TNBC),” presented by David Arguello, Ph.D., Caris Life Sciences. Poster #P3-07-30.
- “Comprehensive profiling of metaplastic breast carcinoma reveals frequent over-expression of PD-L1,” presented by Zoran Gatalica, Ph.D., Caris Life Sciences. Poster #P3-07-47.
Friday, December 11, 2015, 7:30 – 9:00 a.m. CT, Halls A-B
Poster Session 4: Tumor Cell and Molecular Biology: Biomarkers
- “Comprehensive multiplatform molecular profiling identifies potentially targetable biomarkers in malignant phyllodes tumors of the breast,” presented by Zoran Gatalica, Ph.D., Caris Life Sciences. Poster #P4-09-19.
- “ABC transporter expression: clues into chemoresistance of triple negative breast cancers,” presented by Rebecca Feldman, Ph.D., Caris Life Sciences. Poster #P4-09-27.
“Caris Life Sciences remains committed to bringing personalized cancer care to patients today,” added Dr. Reddy. “By elevating the level of clarity and personalization in cancer diagnosis, treatment and research, we are helping oncologists save time, optimize treatment efficacy, reduce patient suffering, and potentially lower the overall cost of treatment for patients.”
About Caris Life Sciences®
Caris Life Sciences® is a leading biotechnology company focused on fulfilling the promise of precision medicine through quality and innovation. Caris Molecular Intelligence®, the company’s healthcare information and comprehensive tumor profiling service with more than 80,000 patients profiled, provides oncologists with the most clinically actionable treatment options available to personalize cancer care today. Using a variety of advanced profiling technologies to assess relevant biological changes in each patient’s tumor, Caris Molecular Intelligence connects biomarker data generated from a tumor with biomarker-drug associations supported by evidence in the relevant clinical literature. Since 2009, Caris Life Sciences has tracked clinical and outcome data for certain patients undergoing tumor profiling, and has observed that patients treated with drugs consistent with their tumor profile show a significant increase in overall survival. The company is also developing its ADAPT Biotargeting System™, a revolutionary and unbiased profiling platform with applications across therapy development, drug delivery, advanced diagnostics and disease monitoring. Currently being developed for cancer and other complex diseases, the ADAPT Biotargeting System is able to simultaneously measure millions of molecular interactions within complex biological systems in their natural state(s). Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Australia and other international markets. To learn more, please visit www.CarisLifeSciences.com.
Caris Life Sciences Media Relations & Corporate Affairs